Tempus AI Targets Share of Cancer Therapy Business

The Wall Street Journal posted about its article on Tempus AI seeking a role supplying Moderna and Merck with services tied to their personalized cancer therapies. The piece names Personalis as central to the bet. It places the effort inside a larger push for cancer vaccines and the supporting tools that companies will need. The post contains no details on contracts, revenue, or results achieved so far.